(Alliance News) - Synairgen PLC, a respiratory drug discovery and development company, on Wednesday said that it has received expedited approvals from two UK regulators to trial SNG001, inhaled formulation of interferon-beta-1a, in Covid-19 patients to potentially assist with the global outbreak of the virus.
The company received expedited approvals from the UK Medicines & Healthcare Products Regulatory Agency and Health Research Authority.
Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection, the company said.
Synairgen's Phase II trial in Covid-19 patients will be a double-blind, placebo-controlled trial. Initially, the pilot phase of the study will involve 100 Covid-19 patients.
Shares in Synairgen closed 1.0% lower at 24.25 pence each in London on Wednesday.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)